{"schema_version":"secwatch.filing_event.v1","accession":"0001739104-23-000021","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.269484+00:00","generated_at":"2026-06-08T16:32:46.353375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elanco reports Q3 2023 net loss of $1,096M on $1,042M goodwill impairment; raises adjusted EPS guidance","bullets":["Revenue $1,068M (+4% reported, +5% CC); Pet Health +6% CC, Farm Animal +4% CC.","Reported net loss $1,096M includes $1,042M goodwill impairment; adjusted EPS $0.18 (up 6% YoY).","Full-year 2023 guidance tightened: revenue $4,360-4,400M, adj. EPS $0.88-0.94 (prior $0.80-0.89).","Net leverage ratio 5.7x; Q4 guidance: revenue $978-1,018M, adj. EPS $0.07-0.13.","CEO: innovation pipeline Credelio Quattro, Bovaer, Zenrelia on track for H1 2024 US approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001739104-23-000021","json":"https://secwatch.observer/filing/0001739104-23-000021.json","markdown":"https://secwatch.observer/filing/0001739104-23-000021.md","text":"https://secwatch.observer/filing/0001739104-23-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/0001739104-23-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/elan-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:32:46.353375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48e47146fe89e5c6e1991e583bfa45ac3893495a","claim":"Elanco Animal Health Inc reported the fiscal quarter ended September 30, 2023 results: revenue Revenue of $1,068 million, net income Reported Net Loss of $1,096 million, EPS Reported EPS of $(2.22).","evidence_excerpt":"Elanco Animal Health Reports Third Quarter 2023 Results • Third Quarter 2023 Financial Results ◦ Revenue of $1,068 million, representing 4% reported growth or 5% excluding the impact of foreign exchange rates ◦ Reported Net Loss of $1,096 million, inclusive of a non-cash goodwill impairment charge of $1,042 million primarily related to increased long-term treasury rates ◦ Adjusted EBITDA of $214 million, or 20.0% of Revenue ◦ Reported EPS of $(2.22) inclusive of a $(2.10) per share impact of goodwill impairment charge, Adjusted EPS of $0.18","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/0001739104-23-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"Revenue of $1,068 million"},{"label":"Net income","value":"Reported Net Loss of $1,096 million"},{"label":"EPS","value":"Reported EPS of $(2.22)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6d5ea29881200fc6bb8ca91e224026c3aee60f63","claim":"Elanco Animal Health Inc reported full year 2023 results: revenue Revenue of $4,360 to $4,400 million, net income Reported Net Loss of $1,174 to $1,204 million, EPS Reported diluted EPS of $(2.43) to $(2.37).","evidence_excerpt":"Updating full year 2023 guidance to reflect third quarter outperformance offset by expected unfavorable impact of foreign exchange rates: ◦ Revenue of $4,360 to $4,400 million, constant currency growth improves to flat to 1% ◦ Reported Net Loss of $1,174 to $1,204 million, Reported diluted EPS of $(2.43) to $(2.37) ◦ Adjusted EPS of $0.88 to $0.94, Adjusted EBITDA of $965 to $1,000 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/0001739104-23-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"Revenue of $4,360 to $4,400 million"},{"label":"Net income","value":"Reported Net Loss of $1,174 to $1,204 million"},{"label":"EPS","value":"Reported diluted EPS of $(2.43) to $(2.37)"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}